Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Current Leases (2019 - 2026)

Protara Therapeutics' Current Leases history spans 8 years, with the latest figure at $1.3 million for Q1 2026.

  • Quarterly Current Leases rose 8.03% to $1.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Mar 2026, up 8.03% year-over-year, with the annual reading at $1.2 million for FY2025, 10.5% up from the prior year.
  • Current Leases came in at $1.3 million for Q1 2026, up from $1.2 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.3 million in Q1 2026 to a low of $870000.0 in Q1 2022.
  • The 5-year median for Current Leases is $1.0 million (2024), against an average of $1.0 million.
  • The largest YoY upside for Current Leases was 845.65% in 2022 against a maximum downside of 7.14% in 2022.
  • Protara Therapeutics' Current Leases stood at $917000.0 in 2022, then grew by 7.2% to $983000.0 in 2023, then increased by 14.34% to $1.1 million in 2024, then rose by 10.5% to $1.2 million in 2025, then grew by 1.77% to $1.3 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Current Leases are $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025).